Evaluation of biomarkers in the studies of keloid tissue after laser therapy
https://doi.org/10.21518/2079-701X-2022-16-5-25-30
Abstract
The main metabolite of lactobacilli, regulating their anti-inflammatory functions, is lactic acid (LA), which maintains the physiological state of the microbiocenosis of the vagina of women of reproductive age. Normocenosis of the vagina is based on a combination of acidic environment and colonization resistance. Pathogenic and conditionally pathogenic pathogens are colonized mainly in an alkaline environment. LA is an important biological substrate that supports the vaginal microbiota. Normally, the reaction of the vaginal contents is a pH of 3.8 to 4.5, and only in this case lactobacilli predominate in the biotope, which are able to unite into special communities – biofilms, forming the most powerful factor in protecting the vagina from adhesion and invasion of pathogens: a full-fledged lactobacillary biofilm is often able to prevent adhesion of even STI pathogens. Disruption of the functioning of each of the links of protection of the vaginal microbiome leads to a change in the pH of the habitat and excessive reproduction of conditionally pathogenic microorganisms. A frequent infectious syndrome, accompanied by an imbalance of the vaginal microbiota and the replacement of lactoflora with various types of anaerobic microorganisms (Gardnerella vaginalis, Ureaplasma urealyticum, Mycoplasma hominis, Mobiluncus, Prevotella), is bacterial vaginosis. When prescribing antibacterial treatment, side effects are possible: allergic reactions, hepatotoxic, nephrotoxic, candidiasis. The review presents the possibility of using LA, which is a basis in the composition of the drug Lactodepantol (Femilex®) – vaginal suppositories containing 100 mg of LA, as the main factor regulating the natural composition of the vaginal microbiota and the possibility of using vaginal suppositories based on LA (lactodepantol) for the prevention and treatment of bacterial vaginosis in the form of monotherapy and in combination with antimicrobials.
About the Authors
A. L. Tikhomirov
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Aleksander L. Tikhomirov, Dr. Sci. (Med.), Honored Doctor of the Russian Federation, Professor, Professor of the Department of Obstetrics and Gynecology of the Medical Faculty
20, Bldg. 1, Delegatskaya St., Moscow, 127473
V. V. Kazenashev
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Victor V. Kazenashev, Cand. Sci. (Med.), Assistant of the Department of Obstetrics and Gynecology of the Medical Faculty
20, Bldg. 1, Delegatskaya St., Moscow, 127473
References
1. Savelyeva G.M., Sukhoi G.T., Serov V.N., Radzinsky V.E., Manukhin I.B. Gynecology: National guidelines. Moscow: GEOTAR-Media; 2020. 1056 р. (In Russ.)
2. Bradshaw C.S., Brotman R.M. Making inroads into improving treatment of bacterial vaginosis – striving for long-term cure. BMC Infect Dis. 2015;15:292. https://doi.org/10.1186/s12879-015-1027-4.
3. Peebles K., Velloza J., Balkus J.E., McClelland R.S., Barnabas R.V. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis. Sex Transm Dis. 2019;46(5):304–311. https://doi.org/10.1097/OLQ.0000000000000972.
4. Kira E.F. Bacterial vaginosis. Moscow: MIA; 2012. 472 p. (In Russ.)
5. Koumans E.H., Sternberg M., Bruce C., McQuillan G., Kendrick J., Sutton M., Markowitz L.E. The prevalence of bacterial vaginosis in the United States, 2001–2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007;34(11):864–869. https://doi.org/10.1097/OLQ.0b013e318074e565.
6. Smith S.B., Ravel J. The vaginal microbiota, host defence and reproductive physiology. J Physiol. 2017;595(2):451–463. https://doi.org/10.1113/JP271694.
7. Brooks J.P., Buck G.A., Сhen G., Diao L., Edwards D.J., Fettweis J.M. Changes in vaginal community state types reflect major shifts in the microbiome. Мicrobial Ecology in Health and Disease. 2017;28:1303265. https://doi.org/10.1080/16512235.2017.1303265.
8. Donders G. Diagnosis and management of bacterial vaginosis and other types of abnormal vaginal bacterial flora: review. Obstet Gynecol Surv. 2010;65(7):462–473. https://doi.org/10.1097/OGX.0b013e3181e09621.
9. Witkin S.S., Mendes-Soares H., Linhares I.M., Jayaram A., Ledger W.J., Forney L.J. Influence of Vaginal Bacteria and d- and l-Lactic Acid Isomers on Vaginal Extracellular Matrix Metalloproteinase Inducer: Implications for Protection against Upper Genital Tract Infections. MBio. 2013;4(4):e00460–13. https://doi.org/10.1128/mbio.00460-13.
10. Rose W.A., Mcgowin C.L., Spagnuolo R.A., Eaves-Pules T.D., Popov V.L., Pules V.D. Commensal bacteria modulate innate immune responses of vaginal epithelial cell multilayer cultures. PLoS ONE. 2012;(7):e32728. https://doi.org/10.1371/journal.pone.0032728.
11. Balkus J.E., Mitchell C., Agnew K., Liu C., Fiedler T., Cohn S.E. et al. Detection of hydrogen peroxide-producing Lactobacillus species in the vagina: a comparison of culture and quantitative PCR among HIV-1 seropositive women. BMC Infect Dis. 2012;12:188. https://doi.org/10.1186/1471-2334-12-188.
12. Brusselaers N., Shrestha S., van de Wijgert J., Verstraelen H. Vaginal dysbiosis and the risk of human papillomavirus and cervical cancer: systematic review and meta-analysis. Am J Obstet Gynecol. 2019;221(1):9–18.e8. https://doi.org/10.1016/j.ajog.2018.12.011.
13. Donders G.G., Van Calsteren C., Bellen G., Reybrouck R., Van den Bosch T., Riphagen I., Van Lierde S. Association between abnormal vaginal flora and cervical length as risk factors for preterm birth. Ultrasound Obstet Gynecol. 2010. https://doi.org/10.1002/uog.7568.
14. Pustotina O.A. Bacterial vaginosis: pathogenesis, diagnosis, treatment, and prevention. Akusherstvo i Ginekologiya (Russian Federation). 2018;(3):150–156. (In Russ.) Available at: http://pustotina.ru/docs/bakterialnyj-vaginozpatogenez-diagnostika-lechenie-i-profilaktika.pdf.
15. Radzinsky V.E. Obstetric aggression. Moscow; 2017. 872 р. (In Russ.) Available at: https://akusher-lib.ru/wp-content/uploads/2018/11/Akusherskaya-agressiya-v.-2.0.pdf?ysclid=l0ruyk6ti0.
16. Abbai N.S., Reddy T., Ramjee G. Prevalent bacterial vaginosis infection—a risk factor for incident sexually transmitted infections in women in Durban, South Africa. Int J STD AIDS. 2016;27(14):1283–1288. https://doi.org/10.1177/0956462415616038.
17. Lokken E.M., Balkus J.E., Kiarie J., Hughes J.P., Jaoko W., Totten P.A. et al. Association of recent bacterial vaginosis with acquisition of Mycoplasma genitalium. Am J Epidemiol. 2017;186(2):194–201. https://doi.org/10.1093/aje/kwx043.
18. Gosmann C., Anahtar M.N., Handley S.A., Farcasanu M., Abu-Ali G., Bowman B.A. et al. Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. Immunity. 2017;46(1):29–37. https://doi.org/10.1016/j.immuni.2016.12.013.
19. McClelland R.S., Lingappa J.R., Srinivasan S., Kinuthia J., John-Stewart G.C., Jaoko W. et al. Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study. Lancet Infect Dis. 2018;18(5):554–564. https://doi.org/10.1016/S1473-3099(18)30058-6.
20. Kenyon C.R., Buyze J., Klebanoff M., Brotman R.M. Association between bacterial vaginosis and partner concurrency: a longitudinal study. Sex Transm Infect. 2018;94(1):75–77. https://doi.org/10.1136/sextrans-2016-052652.
21. Bautista C.T., Wurapa E., Sateren W.B., Morris S., Hollingsworth B., Sanchez J.L. Bacterial vaginosis: a synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections. Mil Med Res. 2016;3:4. https://doi.org/10.1186/s40779-016-0074-5.
22. Gondwe T., Ness R., Totten P.A., Astete S., Tang G., Gold M.A. et al. Novel bacterial vaginosis-associated organisms mediate the relationship between vaginal douching and pelvic inflammatory disease. Sex Transm Infect. 2020;96(6):439–444. https://doi.org/10.1136/sextrans-2019-054191.
23. Swidsinski A., Mendling W., Loening-BauckeV., Ladhoff A., Swidsinski S., Hale L.P., Lochs H. Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 2005;106(5 Pt 1): 1013–1023. https://doi.org/10.1097/01.AOG.0000183594.45524.d2.
24. Bradshaw C.S., Morton A.N., Hocking J., Garland S.M., Morris M.B., Moss L.M. et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478–1486. https://doi.org/10.1086/503780.
25. Muzny C.A., Schwebke J.R. Biofilms: an underappreciated mechanism of treatment failure and recurrence in vaginal infections. Clin Infect Dis. 2015;61(4):601–604. https://doi.org/10.1093/cid/civ353.
26. Sullivan A., Edlund C., Nord C.E. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect. Dis. 2001;(2):101–114. https://doi.org/10.1016/S1473-3099(01)00066-4.
27. Mossop H., Linhares I.M., Bongiovanni A.M., Ledger W.J., Witkin S.S. Influence of lactic acid on endogenous and viral RNA-induced immune mediator production by vaginal epithelial cells. Obstet Gynecol. 2011;118(4):840–846. https://doi.org/10.1097/AOG.0b013e31822da9e9.
28. Kira E.F., Prilepskaya V.N., Kostava M.N., Gamirova E.V., Dovletkhatova E.R., Dushkina E.A. Modern approaches to the choice of locally applied drug in the therapy of bacterial vaginosis. Akusherstvo i Ginekologiya (Russian Federation). 2012;(7):59–67. (In Russ.) Available at: https://aig-journal.ru/ articles/Sovremennye-podhody-k-vyboru-preparata-lokalnogo-deistviya-vterapii-bakterialnogo-vaginoza.html.
29. Kira E.F., Dushkina E.A., Badikova N.S. Biological role of vaginal acidity. stability mechanisms and correction methods. Akusherstvo i Ginekologiya (Russian Federation). 2013;(3):102– 106. (In Russ.) Available at: https://aig-journal.ru/articles/Biologicheskaya-rol-kislotnosti-vlagalishaMehanizmy-stabilnosti-i-metody-korrekcii.html.
30. Kira E.F., Pekarev O.G., Molchanov O.L., Maltseva L.I., Aksenenko V.A., Selikhova M.S. et al. Comparative analysis of the safety effectiveness of a parallel or sequential combination of metronidazole with lactic acid and a two-stage method of metronidazole plus probiotic. Multicenter randomized controlled trial. Akusherstvo i Ginekologiya (Russian Federation). 2016;(9):87–93. (In Russ.) https://doi.org/10.18565/aig.2016.9.87-93.
31. Kira E.F., Korshakova N.Yu. An open randomized placebo-controlled study of the efficacy and safety of monotherapy of bacterial vaginosis with the vaginal use of lactic acid. Akusherstvo i Ginekologiya (Russian Federation). 2018;(5):96–101. (In Russ.) https://doi.org/10.18565/aig.2018.5.96-101.
32. Kira E.F., Rybalchenko O.V., Orlova O.G., Korshakova N.Yu. To study the activity of lactic acid in vitro and its significance for clinical practice in the treatment of vaginal infections. Akusherstvo i Ginekologiya (Russian Federation). 2017;(11):84–90. (In Russ.) Available at: https://aig-journal.ru/ articles/Izuchenie-aktivnosti-molochnoi-kisloty-in-vitro-i-ee-znacheniedlya-klinicheskoi-praktiki-v-lechenii-infekcii-vlagalisha.html.
Review
For citations:
Tikhomirov AL, Kazenashev VV. Evaluation of biomarkers in the studies of keloid tissue after laser therapy. Meditsinskiy sovet = Medical Council. 2022;(5):25-30. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-5-25-30
Views:
465
Email this article 